suggested remit : To appraise the clinical and cost effectiveness of Epicutaneous immunotherapy skin patch within its marketing authorisation for treating Allergy (peanut, children)
Status Proposed
Process STA 2018
ID number 1255

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
24 November 2020 - 21 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance